Versus Systems Inc logo

VS - Versus Systems Inc News Story

C$12.65 0.2  1.2%

Last Trade - 25/02/21

Small Cap
Market Cap £65.8m
Enterprise Value £65.6m
Revenue £798k
Position in Universe 820th / 2713

Versus Systems Partners With Predictmedix to Develop Products for Healthcare Applications in the Clinical Trial Market

Thu 1st October, 2020 1:30pm
For best results when printing this announcement, please click on link below:

LOS ANGELES, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Versus Systems Inc.
(“Versus”) (CSE:VS) (OTCQB:VRSSF) (FRANKFURT:BMVA) today signed an
agreement with Predictmedix, Inc. (“Predictmedix”) (CSE:PMED)
(OTCQB:PMEDF), a medical software company that integrates Artificial
Intelligence “AI” into healthcare testing technology. The agreement is to
bring Versus’ proprietary rewards platform to the healthcare vertical –
allowing healthcare providers, Contract Research Organizations (CROs), and
life science companies to use rewards to recruit and retain a broader range of
patients, and to promote compliance in testing medical therapies. These
products, for use primarily by CROs, academic medical centers and those in the
clinical trials markets, will enter a market that Fortune Business Insights
estimates at $40 Billion USD annually.(1)

Predictmedix will use Versus’s patented rewards and engagement engine to
incentivize users and patients to take steps in their treatment. In the case
of clinical trials, this may include rewarding patients for joining certain
trials, as well as for complying with trial protocols. According to Deloitte,
recruiting, retention, and compliance are central issues in the clinical trial
space with over 40% of patients not adhering to trial protocols.(2) The Versus
IP allows for remote data collection, real-time feedback, and a rewards-based
engagement that could change patient behaviors and outcomes - saving time and
money, and also improving healthcare outcomes by providing more complete trial



About Predictmedix, Inc.

Predictmedix Inc. is an artificial intelligence ("AI") company developing
disruptive tools for impairment testing and healthcare. Predictmedix is
developing AI based screening for the healthcare industry. The recent advent
of COVID-19 pandemic has placed unprecedented stress on the global economy and
highlights the need for tools to help screen mass populations for infectious
diseases, with the hope of preventing pandemics in the future. In turn,
Predictmedix Inc. is expanding its proprietary AI technology to screen for
infectious diseases for identification of symptomatic individuals.

Additionally, psychiatric disorders such as depression, dementia and
Alzheimer's disease can carry a significant burden and early identification is
the key to better management. To help address this, Predictmedix is also
expanding its proprietary AI technology to screen for psychiatric and/or brain
disorders such as depression, dementia and Alzheimer's disease. To find out
more visit us at

Disclaimer: "Predictmedix is not making any express or implied claims that its
product has the ability to diagnose, eliminate, cure or contain the Covid-19
(or SARS-2 Coronavirus) at this time."

For further information, please contact:

Dr. Rahul Kushwah, Chief Operating Officer
Tel: 647 889-6916

About Versus Systems

Versus Systems, Inc. has developed a proprietary in-game prizing and
promotions engine that allows game publishers and developers to offer in-game
and in-app prizing across mobile, console, PC games, and streaming media.
Brands pay to place products in-game and gamers compete for those prizes. For
more information, please visit or visit the official
Versus Systems YouTube channel

For Versus Systems, contact:
Cody Slach, Sean McGowan
Gateway Investor Relations

Disclaimer for Forward-Looking Information 

This news release contains certain forward-looking information and
forward-looking statements within the meaning of the applicable Canadian
securities legislation. All statements, other than statements of historical
fact, are forward looking statements and are based on expectations, estimates
and projections as at the date of this news release. Any statement that
involves discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, assumptions, future events or performance
(often but not always using phrases such as "expects", or "does not expect",
"is expected", "anticipates" or "does not anticipate", "plans", "budget",
"scheduled", "forecasts", "estimates", "believes" or "intends" or variations
of such words and phrases or stating that certain actions, events or results
"may" or "could", "would", "might" or "will" be taken to occur or be achieved)
are not statements of historical fact and may be forward looking statements.
In this news release, forward-looking statements relate, among other things,
to the inclusion of Versus’ proprietary rewards platform in the healthcare
vertical under the agreement with Predictmedix, Inc. and the potential of
improving healthcare outcomes through Versus’ IP by providing more complete
trial data. These forward-looking statements are based on reasonable
assumptions and estimates of management of the Company at the time such
statements were made. Actual future results may differ materially as
forward-looking statements involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements
of the Company to materially differ from any future results, performance or
achievements expressed or implied by such forward-looking statements. Although
the forward-looking statements contained in this news release are based upon
what management of the Company believes, or believed at the time, to be
reasonable assumptions, the Company cannot assure shareholders that actual
results will be consistent with such forward-looking statements, as there may
be other factors that cause results not to be as anticipated, estimated or
intended. Accordingly, readers should not place undue reliance on
forward-looking statements and information. There can be no assurance that
forward-looking information, or the material factors or assumptions used to
develop such forward-looking information, will prove to be accurate. The
Company does not undertake any obligations to release publicly any revisions
for updating any voluntary forward-looking statements, except as required by
applicable law. 

The Canadian Securities Exchange does not accept responsibility for the
adequacy or accuracy of this press release.


GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.